![]() |
|
|
Tufts University, Boston, MA 02111
3 To whom correspondence should be addressed. E-mail: jmason{at}hnrc.tufts.edu.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: biomarkers diet assessment epidemiology folate nutrition one-carbon metabolism
One-carbon metabolism is a network of interrelated biochemical reactions that involve the transfer of one-carbon groups from one site to another (Fig. 1) (1). It is more accurate to refer to this network of reactions as one-carbon metabolism than methyl metabolism because the one-carbon moiety, depending on the particular reaction, can be donated in the form of a methenyl, formyl or methyl group. The past decade witnessed a renewed interest in dietary components that mediate, or in some manner facilitate, one-carbon metabolism. The dietary components of interest are the B-vitamins, folate and vitamin B-12, as well as choline and methionine. Collectively, these nutrients are sometimes called "dietary lipotropes," a term that arose from the observation that a diet deficient in choline alone, or choline in combination with other lipotropes, leads to an excessive accumulation of triglyceride in the liver of laboratory rodents.
|
A renewed interest in these compounds was largely engendered by recent indications that modest dietary inadequacies of certain lipotropes can cause several disease conditions of considerable clinical import. Inadequate folate intake early in pregnancy now unequivocally is shown to increase the risk of births complicated by a neural tube defect (NTD)(4). Inadequate intake of folate, vitamin B-12 or vitamin B-6 raises serum levels of a one-carbon intermediary product, homocysteine, which is highly associated with an increased risk of occlusive vascular disease (5). Inadequate intake of folate and methionine (and more recently, vitamins B-6 and B-12) is increasingly implicated in carcinogenesis in certain tissues (6). Our concepts about what constitutes a "deficiency state" for each of these nutrients is in evolution because the abovementioned diseases seem to result from degrees of nutrient depletion that fall far short of the magnitude of depletion that is classically defined as a deficiency state. For example women who consume lesser amounts of folate are at increased risk of delivering an infant with a neural tube defect even though their mean intake is well within a range that prevents the classical deficiency syndrome, megaloblastic anemia, from occurring. Thus there is considerable interest in either redefining normative ranges for desirable blood levels for some of the lipotropes or developing novel, and more revealing, means of assessing nutrient status.
The interest in the dietary determinants of methyl metabolism as it relates to chronic disease largely pertains to various degrees of deficiency rather than excess. This review therefore emphasizes the assessment of nutrient deficiency rather than toxicity.
| A brief biochemical overview |
|---|
|
|
|---|
It is nevertheless important not to focus solely on biological methylation when one is concerned with lipotrope nutriture because existing hypotheses that attempt to explain how lipotrope deficiency produces chronic disease such as cancer implicate aberrations in nucleotide synthesis as well. In this case the intracellular pool of folate coenzymes can alternatively be routed into a biochemical avenue that leads to the de novo synthesis of thymidine or the purines, adenine and guanine. Interestingly, these two major synthetic pathways appear to compete for folate coenzymes. Under normal circumstances SAdoMet serves as a major regulator in determining whether folate will be routed into one path versus the other, largely through its role as an allosteric inhibitor of methylenetetrahydrofolate reductase (MTHFR) (8).
Polymorphisms in several enzymes, such as methionine synthase and MTHFR, were recently described, and they determine in part how folate coenzymes are distributed between methylation and nucleotide synthesis. For instance, the common 677 mutation in the MTHFR gene inhibits the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, and therefore appears to inhibit methylation reactions and instead favor nucleotide synthesis. This is particularly evident when folate availability is limited. Thus compared to wild-type subjects, under low folate conditions subjects with the homozygous TT (mutant) genotype possess higher blood concentrations of homocysteine owing to impaired remethylation of the compound to methionine (9) as well as lower levels of genomic DNA methylation in their peripheral blood cells (10,11).
| Biomarkers of nutrients involved in methyl metabolism: direct measures of nutrient exposure or status |
|---|
|
|
|---|
| Intakes of nutrients |
|---|
|
|
|---|
|
Habitual dietary intake of a particular nutrient is a major (although not the sole) determinant of nutrient status. Therefore, another means of validating the FFQs is by comparing values obtained from the FFQ with a biochemical indicator of nutrient status. An example of this is shown in Table 2.
|
The relationships between vitamin intake, as assessed by FFQ, and biochemical status are not as robust as those observed when FFQ intakes are compared to diet records. In large part this is because nutrient status is related to many factors, only one of which is dietary intake. A prime example is vitamin B-12. Intake of the vitamin is frequently shown to be only a rough predictor of vitamin B-12 status because common pathophysiological factors, such as the presence of atrophic gastritis, have a very large impact on the bioavailability of food-borne vitamin B-12. The issue is of lesser magnitude with vitamin B-12 supplements because the form of vitamin B-12 in supplements is not protein-bound and therefore not diminished by atrophic gastritis (16).
Habitual intake of methionine is estimated by the Willett FFQ by relying on the methionine content listed in the National Reference Food Tables published by the U.S. Department of Agriculture (www.nalusda.gov/fnic/cgi-bin/nut-search.pl). However, there has been little or no attempt to cross-validate these estimates with dietary records or biochemical indices. Dietary assessment of choline intake is even more difficult because standards for the choline content of foods are not yet published by the USDA. Nevertheless individual research laboratories have published tables indicating the choline content of common foods (17).
| Conventional biochemical assessment of nutrient status |
|---|
|
|
|---|
Historically the serum (or plasma) folate concentration and red blood cell (RBC) concentration of folate were the two most commonly used indicators of folate status. In the human, serum folate tends to be more a reflection of short-term folate balance during the preceding 12 d (18). The measurement of serum folate nevertheless has substantial predictive value in defining the risk of megaloblastic anemia as well as other indicators of systemic folate status, such as homocysteine levels (19). In contrast, the folate that is packaged into a developing blood cell (which is primarily a function of folate availability at the time of erythropoiesis) is no longer metabolized after maturation of that red cell occurs. Red cell folate concentration therefore represents an integration of dietary folate intake during the preceding 120 d, the half-life of a red cell. It is therefore not surprising that RBC folate tends to be a more accurate reflection of tissue folate status (18), because the latter is also largely determined by habitual intake over a prolonged period. Although normative values vary somewhat from laboratory to laboratory, two standard deviations below the mean for serum and RBC folate concentrations are typically 3 ng/mL and 160 ng/mL, respectively, and values less than that are associated with a markedly increased risk of developing megaloblastic anemia (18); serum folate concentrations of 35 ng/mL are considered to be marginally deficient. Serum and RBC folate continue to be important tools in the clinical evaluation of folate status although it is worth remembering that what we presently consider to be acceptable normative ranges may need to be modified in view of the growing consensus that subtle degrees of folate depletion of insufficient magnitude to cause megaloblastic anemia appear to have pathologic consequences.
Depletion of folate does not occur in a symmetric fashion among the various tissues of the body. Animal models of folate depletion clearly demonstrate that some tissues are more susceptible to depletion than others (20). Therefore, the measurement of the folate content in the tissue of interest may provide additional important information. Because methylated forms of folate generally participate in methylation reactions whereas nonmethylated forms play other physiologic roles, recent work suggests that measurement of the distribution of different coenzymatic forms of folates in a tissue has important meaning in terms of the functional capability of that tissue to carry out methylation reactions (21). Because of recent technological advances, the means of assessing the distribution of folate coenzymes is now feasible in small tissue samples such as biopsies (22).
Vitamin B-12.
The serum cobalamin assay remains the conventional means of assessing vitamin B-12 status. Two standard deviations below the mean are typically found to be 150 pg/mL, and levels below that are clearly associated with a high risk of developing clinical manifestations of vitamin B-12 deficiency (23).
Some individuals develop clinical manifestations of vitamin B-12 deficiency even though their serum B-12 level is in the low-to-normal range, i.e., 150400 pg/mL (24). It has been estimated that up to 515% of the elderly whose serum B-12 falls in this range are functionally deficient in vitamin B-12 (25). The measurement of serum methylmalonic acid (MMA) and homocysteine were shown to be effective means of detecting such subtle deficiencies although MMA is more specific because it does not also rise in folate deficiency (26). Nevertheless, confounding factors that may artifactually alter MMA levels include renal insufficiency or hypovolemia (27) and concurrent use of antibiotics (28). Measuring levels of the serum transport protein, transcobalamin II bound to cobalamin, has been suggested as a sensitive means of detecting vitamin B-12 depletion (29) although it has not been explored as extensively as MMA and homocysteine.
Vitamin B-6.
The major form of vitamin B-6 in the circulation is pyridoxial-5'-phosphate (PLP), the concentration of which is often used as an indicator of vitamin B-6 status. It is among the most sensitive measures of systemic vitamin B-6 status available although various reports suggest it may be influenced by factors such as physical exercise, pregnancy and the level of plasma alkaline phosphatase (30). Other measures of human vitamin B-6 status include erythrocyte PLP, total plasma B-6, urinary excretion of either total B-6 or a metabolite, 4-pyridoxic acid, or the activation coefficients of either of two erythrocyte enzymes dependent on vitamin B-6: alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Among these, the urinary excretion of 4-pyridoxic acid or total B-6 appear to reflect recent dietary intake of the vitamin whereas the enzyme activity coefficients are reflective of long-term intake. In addition, the urinary excretion of xanthurenic acid after an oral tryptophan load is sometimes used as a functional indicator of vitamin B-6 status. Each of these measures of vitamin B-6 status was repeatedly shown to be a valid measure of B-6 status in closely controlled studies in healthy human volunteers (3133). Under these conditions, xanthurenic acid excretion was observed to be the most sensitive indicator (31). However, experience with xanthurenic acid excretion indicates that it is easily affected by numerous confounding factors such as drugs and disease states and therefore its widespread application appears limited outside of carefully controlled studies.
Vitamin B-2.
Riboflavin status is most commonly assessed by measuring flavin adenine dinucleotide (FAD)-dependent glutathione reductase activity in freshly lysed red blood cells before and after addition of FAD (34). This is another so-called "activation coefficient" assay because it assesses how much additional enzyme activity is gained by adding exogenous cofactor. Studies performed under well-controlled depletion and repletion conditions in healthy subjects (35), as well as those performed in large-scale nutrition surveys (36), indicate this is a sensitive measure of vitamin B-2 status.
One limitation of this assessment tool is that the results appear to be artifactually altered in individuals with glucose-6-phosphate dehydrogenase deficiency (37), the most common form of which afflicts
10% of the African-American population in the United States.
Total urinary riboflavin excretion is also used (35) as an indication of riboflavin status. It appears to be more indicative of recent riboflavin intake rather than bodily status of the vitamin, is not as sensitive as the EGR assay and the values obtained during depletion are not proportional to the magnitude of deficiency, as is true of the enzymatic EGR assay (35,36). Plasma and whole blood concentrations of riboflavin are also used but do not appear to be as useful as the EGR assay and urinary riboflavin excretion.
| Selected biochemical parameters that have potential as functional measures of lipotrope status |
|---|
|
|
|---|
Serum or plasma homocysteine.
An elevation in the serum concentration of homocysteine is found to be a sensitive indicator of both folate and vitamin B-12 depletion because the remethylation of homocysteine to methionine is a B-12- and folate-dependent process (an alternative pathway exists, but only in the liver). Studies conducted under metabolic unit conditions indicate that serum homocysteine begins to rise perceptibly before the level of serum folate falls into a frankly deficient range (38). Similarly elevations in homocysteine are more sensitive in subtle vitamin B-12 deficiency than plasma B-12 alone; in the elderly, 510% of true vitamin B-12 deficiencies might be overlooked if plasma B-12 alone is used as a criteria, although in this setting both homocysteine and methylmalonic acid levels should be checked to facilitate the distinction between folate and vitamin B-12 deficiency (26,28). Specificity is a concern in certain settings because chronic renal insufficiency, advancing age (especially >60 y), and chronic alcohol abuse also predictably cause an elevation, although if these factors are taken into account, serum homocysteine appears to be an excellent means of detecting even modest levels of folate or vitamin B-12 depletion. In a large population-based survey of healthy elderly, mean plasma homocysteine was observed to rise when habitual folate intake was <250 µg per d or when serum folate was <2.2 ng/mL (19). In the same study, a significant rise in plasma homocysteine was observed when plasma B-12 dropped below 190 pg/mL. Other factors that should be taken into account (39) include gender, because before menopause men have higher homocysteine levels than women, hypothyroidism (40), regular use of coffee (41), as well as the use of drugs such as folate antagonists and L-dopa.
In contrast to vitamin B-12 and folate, an elevation in fasting plasma homocysteine is not a reliable indicator of vitamin B-6 depletion because, in the vitamin B-6deplete fasting state, homocysteine disposal occurs readily through the alternative remethylation pathway (42) (Fig. 1). In a nonfasting state, elevations in homocysteine become more reflective of defective vitamin B-6 status because the alternative pathway for homocysteine disposal is inhibited. Thus in large observational studies, nonfasting plasma homocysteine concentrations correlate inversely with dietary vitamin B-6 intake and plasma PLP levels quite well (19). Nevertheless, the accuracy with which a postprandial homocysteine concentration can diagnose vitamin B-6 depletion in an individual subject is not yet well defined. For the purposes of increasing the rigor of scientific studies, postprandial homocysteine concentrations are usually mimicked by instead administering a standardized oral dose of methionine (100 mg/kg) and then measuring the plasma homocysteine concentration 24 h after the methionine load (43).
S-adenosylmethionine (S-AdoMet) and S-adenosylhomocysteine (SAH).
The concentrations of S-AdoMet and SAH are in large part determined by adequate availability of lipotropes and therefore they constitute functional reflections of lipotrope status. Of additional importance is the fact that S-AdoMet serves as the proximate methyl donor for nearly all the biochemical reactions that result in the methylation of DNA, RNA, phospholipids, proteins and other macromolecules (Fig. 1). Increased tissue concentrations of S-AdoMet, as well as decreased concentrations of SAH generally correlate with the extent to which these macromolecular methyl acceptors becomes methylated (7) although it is important to note that perturbation of the S-AdoMet:SAH ratio is not invariably reflected in altered methylation of macromolecules (44). The measurement of S-AdoMet and SAH therefore has added potential as a functional indicator of methylation capability.
Many studies in animals indicate that folate, methionine, choline or vitamin B-12 deficiencies each promptly lead to diminished levels of hepatic S-AdoMet, often to rises in hepatic SAH, and usually to a significant decrease in the SAM:SAH ratio (4446). SAH tends to rise in any situation where homocysteine levels are increased because the hydrolysis of SAH to homocysteine is reversible and thermodynamically favors the reverse reaction (Fig. 1).
Despite the attractive nature of using S-AdoMet and SAH as indicators of lipotrope status and methylation capacity, one must keep in mind that the measurement of these metabolites in a single tissue does not necessarily mean that this measurement is representative of the state of affairs in every tissue. For instance, in one rodent study of folate depletion no concurrent alterations in S-AdoMet and SAH occurred in the colonic mucosa as was observed in the liver (45).
There is only a small amount of data defining how S-AdoMet and SAH concentrations in humans are altered by lipotrope deficiencies, largely because there was no way to reliably measure S-AdoMet and SAH in the plasma until very recently. However, there is now a published HPLC method with coulometric detection for measuring S-AdoMet and SAH in plasma (47). In healthy controls, elevations in plasma SAH are observed to be associated with higher homocysteine concentrations and low plasma pyridoxal-5'-phosphate (47,48). Nevertheless, no one has yet quantitatively defined the relationships between plasma S-AdoMet, SAH and the lipotrope nutrients in any detail. However, the use of plasma SAH in particular looks promising as a biomarker because the existing data shows excellent correlations between it and other presumptive functional markers of lipotrope status. For example, the correlation between plasma homocysteine and plasma SAH is reported to be quite strong (r = 0.73, p < 0.001). Plasma SAH correlates inversely with genomic DNA methylation in blood lymphocytes in an equally strong fashion (r = -0.74, p < 0.001), consistent with the concept that SAH is an inhibitor of most methylation reactions. In contrast, plasma S-AdoMet has no significant correlation with either plasma homocysteine or DNA methylation, although the existing data also indicates that plasma S-AdoMet:SAH ratios are diminished in individuals with elevated homocysteine levels (48). These observations are entirely consistent with the known determinants of homocysteine and SAH levels, as discussed earlier in this review. Thus initial data suggests that plasma SAH as well as the S-AdoMet:SAH ratio in humans may provide meaningful data about lipotrope status, although considerable work needs to be performed to fully define the qualitative and quantitative nature of the relationship.
Genomic DNA methylation.
Approximately 4% of the cytosine residues in the dinucleotide sequence, CG, are methylated in the human genome.
The patterns of methylation are highly conserved after each replication of a cell, a function performed by specific DNA methyltransferases that utilize S-AdoMet as a methyl donor. The stringent degree of conservation is important because these patterns serve several important functions, including the control of gene transcription and genetic stability. A detailed discussion of these functions of DNA methylation is beyond the scope of this discussion, but is reviewed elsewhere (49). It is particularly pertinent that aberrations of DNA methylation are essentially a universal phenomenon for most cancers. Genomic DNA hypomethylation is generally observed concurrent with selected loci (often within the promoter regions of genes) of hypermethylation. Mechanistically, it was proposed that hypomethylation within the coding region of a gene might create DNA instability and mutations, that hypomethylation in the promoter region of a protooncogene could cause inappropriate overexpression of that gene whereas hypermethylation in a promoter region could repress the expression of important tumor suppressor genes (49).
A combined deficiency of methionine, choline, folate and vitamin B-12 (50), or a marked deficiency of folate alone (51), are shown to induce genomic DNA hypomethylation in laboratory rodents. However, a more moderate degree of folate depletion, even when maintained for several months does not appear to be sufficient to induce genomic hypomethylation (44). Interestingly, in a rodent experiment, multiple lipotrope deficient diets have been shown initially to create loci-specific hypomethylation, which later evolve into loci of hypermethylation, probably as a compensatory response (52). Thus lipotrope depletion appears to be capable of creating paradoxical hypermethylation at selected loci, at least in animal models.
Genomic DNA methylation is emerging as a sensitive biomarker of dietary folate intake. Two studies in healthy human volunteers independently demonstrated that a folate-deplete diet containing
50120 µg of folate per d for 79 wk was sufficient to induce genomic DNA hypomethylation of blood mononuclear cells and that folate repletion over several weeks caused the hypomethylation to return toward normal (38,53). Of considerable import is the observation that DNA hypomethylation evolved in both studies even though mean plasma folate levels never dropped below the normal range and anemia did not emerge, suggesting that DNA methylation is a rather sensitive tool for the identification of folate depletion. Nevertheless as suggested by Figure 2, rises in plasma homocysteine appear a bit earlier than the evolution of DNA hypomethylation. As mentioned earlier in this review, it is now evident that the ability of low folate status to diminish genomic DNA methylation is dependent on interactions with specific genotypic variants, such as the MTHFR 677 (C to T) polymorphism (10,11). In these studies the combination of the TT genotype and low folate status was the necessary condition to produce genomic hypomethylation; either condition alone was insufficient to induce hypomethylation. Thus a relationship between folate depletion and DNA methylation might only become apparent when genetic or metabolic states impose additional limitations to the methylation system.
|
The measurement of genomic DNA methylation, like the measurement of SAH, holds promise as a functional biomarker of lipotrope status. Both parameters are particularly attractive because they may be useful as integrated measures of the status of multiple lipotropes. Nevertheless, utilizing either of these parameters must be done with the recognition that they are affected by factors other than lipotrope availability. Furthermore, much work must be done to more fully understand the precise quantitative nature of the relationships between these biomarkers and lipotrope status.
Uracil misincorporation into DNA.
Folate is a necessary coenzyme for the de novo synthesis of thymidine from its precursor, uridine. Folate depletion alters the cellular pool of these two nucleosides to favor the latter compound although only the former is normally incorporated into DNA. However, cell culture studies indicate that inhibition of folate metabolism leads to inappropriate insertion of uridine where thymidine should be because of the promiscuous nature of some of the DNA polymerases. A single report in humans (55) suggests that frank folate deficiency leads to excessive uridine (more commonly referred to by its parent base, uracil) incorporation into DNA, a phenomenon that was observed to reverse with vitamin repletion. Although this might prove to be an effective biomarker of folate depletion in the future, there must be some confirmation of the original report for this concept to move forward. Unlike plasma S-AdoMet/SAH levels and DNA methylation, uracil misincorporation should be perceived only as a potential candidate for the functional assessment of folate status.
| SUMMARY AND FUTURE DIRECTIONS |
|---|
|
|
|---|
Given the renewed interest in lipotrope depletion, and particularly the interest focused on subtle degrees of depletion that produce disease states, a great deal of exciting possibilities exist for functional tests of nutrient status that are sensitive to very mild degrees of depletion. Plasma homocysteine, plasma S-AdoMet/SAH and DNA methylation are three such promising candidates, although as "downstream" indicators of nutrient status, they are influenced by factors other than the nutrient status. The data on uracil misincorporation in DNA as a functional indicator of folate status is quite preliminary at this point and must be confirmed before its further development as a biomarker.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
2 This work is supported in part by the U.S. Department of Agriculture, under agreement no. 58-1950-9-001. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the author and do not necessarily reflect the view of the U.S. Department of Agriculture. This work also is supported in part by the National Cancer Institute (R01 CA59005-05S1). ![]()
| LITERATURE CITED |
|---|
|
|
|---|
1. Choi, S.-W. & Mason, J. B. (2000) Folate and carcinogenesis: an integrated scheme. J. Nutr. 130: 129132.
2. Fuller, N. & Bates, C. (1986) The effect of riboflavin deficiency on methylenetetrahydrofolate reductase and folate metabolism in the rat. Br. J. Nutr. 55: 455464.[Medline]
3. Hustad, S., Ueland, P., Vollset, S., Zhang, Y., Bjorke-Monsen, A. L. & Schneede, J. (2000) Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677 polymorphism. Clin. Chem. 46: 10651071.
4. Centers for Disease Control. (1992) Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR. 41(No. RR-14): 17.
5. Boushey, C., Beresford, S., Omenn, G. & Motulsky, A. G. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 10491057.[Abstract]
6. Mason, J. B. & Levesque, T. (1996) Folate: effects on carcinogenesis and the potential for cancer prevention. Oncology 10: 17271743.[Medline]
7. Hoffman, D., Marion, D., Cornatzer, W. & Duerre, J. A. (1980) S-adenosylmethionine and S-adenosylhomocysteine metabolism in isolated rat liver. J. Biol. Chem. 255: 1082210827.
8. Kutzbach, C. & Stokstad, E. (1971) Mammalian methylenetetrahydrofolate reductase: partial purification, properties and inhibition by S-adenosylmethionine. Biochim. Biophys. Acta 250: 459477.[Medline]
9. Jacques, P., Bostom, A., Williams, R., Ellison, R. C., Eckfield, J. H., Rosenberg, I. H., Selhub, J. & Rozen, R. (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93: 79.
10. Stern, L. L., Mason, J. B., Selhub, J. & Choi, S. W. (2000) Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol. Biomarkers Prevent. 9: 849853.
11. Friso, S., Choi, S.-W., Girelli, D., Mason, J. B., Dolnikowski, G., Bagley, P., Olivieri, O., Jacques, P., Rosenberg, I. H., Corrocher, R. & Selhub, J. (2002) A common mutation in the 5,10 methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl. Acad. Sci. USA 99: 56065611.
12. Willett, W. C. (1998) Food frequency methods. In: Nutritional Epidemiology, 2nd Ed. (Willet, W., ed.) pp. 74100, Oxford University Press, New York, NY.
13. Rimm, E., Giovannucci, E., Stampfer, M., Colditz, G. A., Litin, L. B. & Willett, W. C. (1992) Reproducibility and validity of an expanded self-administered semi-quantitative food frequency questionnaire among male health professionals. Am. J. Epidemiol. 135: 11141126.
14. Jacques, P., Sulsky, S., Sadowski, J., Phillips, J. C., Rush, D. & Willett, W. C. (1993) Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am. J. Clin. Nutr. 57: 182189.
15. Giovannucci, E., Stampfer, M., Colditz, G., Rimm, E. B., Trichopoulos, D., Rosner, B. A., Speizer, F. E. & Willett, W. C. (1993) Folate, methionine, and alcohol intake and risk of colorectal adenoma. J. Natl. Cancer Inst. 85: 875884.
16. Suter, P., Golner, B., Goldin, B., Morrow, F. D. & Russell, R. M. (1991) Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology 101: 10391045.[Medline]
17. Zeisel, S. (1998) Choline and phosphatidylcholine. In: Modern Nutrition in Health and Disease, 9th Ed. (Shils, M., Olson, J., Shike, M. & Ross, A. C., eds.) p. 514, Williams, Wilkins, Baltimore, MD.
18. Herbert, V. (1998) Folic acid. In: Modern Nutrition in Health and Disease, 9th Ed. (Shils, M., Olson, J., Shike, M., & Ross, A. C., eds.) pp. 443446, Williams, Wilkins, Baltimore, MD.
19. Selhub, J., Jacques, P., Wilson, P., Rush, D. & Rosenberg, I. H. (1993) Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 270: 26932698.[Abstract]
20. Varela-Moreiras, G. & Selhub, J. (1992) Long-term folate deficiency alters folate content and distribution differentially in rat tissues. J. Nutr. 122: 986991.
21. Bagley, P. & Selhub, J. (1998) A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. U.S.A. 95: 1321713220.
22. Bagley, P. & Selhub, J. (2000) Analysis of folate form distribution by affinity followed by reversed-phase chromatography with electrical detection. Clin. Chem. 46: 404411.
23. Weir, D. & Scott, J. (1998) Vitamin B12 "cobalamin". In: Modern Nutrition in Health and Disease, 9th Ed. (Shils, M., Olson, J., Shike, M. and Ross, A.C., eds.) pp. 447458, Williams, Wilkins, Baltimore, MD.
24. Lindenbaum, J., Healton, E., Savage, D., Brust, J. C., Garrett, T. J., Podelle, E. R., Marcell, P. D., Stabler, S. P. & Allen, R. H. (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N. Engl. J. Med. 318: 17201728.[Abstract]
25. Stabler, S., Lindenbaum, J. & Allen, R. H. (1997) Vitamin B12 deficiency in the elderly: current dilemmas. Am. J. Clin. Nutr. 66: 741749.
26. Savage, D., Lindenbaum, J., Stabler, S. & Allen, R. H. (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am. J. Med. 96: 239246.[Medline]
27. Stabler, S., Marcell, P., Podell, E., Allen, R. H., Savage, D. G. & Lindenbaum, J. (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detercted by capillary gas chromatography-mass spectrometry. J. Clin. Invest. 81: 466471.
28. Lindenbaum, J., Savage, D., Stabler, S. & Allen, R. H. (1990) Diagnosis of cobalamin deficiency: relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations. Am. J. Hematol. 34: 99107.[Medline]
29. Herbert, V. (1994) Staging vitamin B12 status in vegetarians. Am. J. Clin. Nutr. 59 (suppl), 1213S1222S.
30. Sauberlich, H. (1999) Vitamin B-6. In: Laboratory Tests for the Assessment of Nutritional Status, 2nd Ed. pp. 71102, CRC Press, Boca Raton, FL.
31. Kretsch, M., Sauberlich, H., Skala, J. & Johnson, H. L. (1995) Vitamin B6 requirements and status assessment. Am. J. Clin. Nutr. 61: 10911100.
32. Hansen, C., Leklem, J. & Miller, L. (1997) Changes in vitamin B6 status indicators of women fed a constant protein diet with varying levels of vitamin B6. Am. J. Clin. Nutr. 66: 13791385.
33. Huang, Y.-C., Chen, W., Evans, M., Mitchell, M. & Schultz, T. (1998) Vitamin B6 requirement and status assessment of young women fed a high protein diet with various levels of vitamin B6. Am. J. Clin. Nutr. 67: 208213.[Abstract]
34. Sauberlich, H. (1999) Vitamin B-2. In: Laboratory Tests for the Assessment of Nutritional Status, 2nd Ed. pp. 5565, CRC Press, Boca Raton, FL.
35. Tillotson, J. & Baker, E. (1972) An enzymatic measurement of the riboflavin status in man. Am. J. Clin. Nutr. 25: 425431.[Abstract]
36. Sauberlich, H., Judd, J., Nichoalds, G., Broquist, H. P. & Darby, W. J. (1972) Application of the erythrocyte glutathione reductase (EGR) assay in evaluating riboflavin nutritional status in a high school student population. Am. J. Clin. Nutr. 25: 756762.[Abstract]
37. Prentice, A. M., Bates, C., Prentice, A., Welch, S. G., Williams, K. & McGregor, I. A. (1981) The influence of G-6-PD activity on the response of erythrocyte glutationie reductase to riboflavin deficiency. Int. J. Vitam. Nutr. Res. 51: 211216.[Medline]
38. Jacob, R., Gretz, D., Taylor, P., James, S. J., Progribney, I. P., Miller, R. S., Henning, S. M. & Swendseid, M. E. (1998) Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J. Nutr. 128: 12041212.
39. Refsum, H., Ueland, P., Nygard, O. & Vollset, S. E. (1998) Homocysteine and cardiovascular disease. Annu. Rev. Med. 49: 3162.[Medline]
40. Nedrebo, B., Ericsson, U., Nygard, O., Refsum, H., Ueland, P. M., Aakvaag, A., Aanderud, S. & Lien, S. E. (1998) Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 47: 8993.[Medline]
41. Grubben, M., Boers, G., Blom, H., Broekhuizen, R., deJong, R., van Rijt, L., deRuijter, E., Swinhels, D. W., Nagengast, F. B. & Katan, M. B. (2000) Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial. Am. J. Clin. Nutr. 71: 480484.
42. Miller, J., Rebaya-Mercado, J., Russell, R., Shepard, D. C., Morrow, F. D., Cochary, E. F., Sadowski, J. A., Gershoff, S. N. & Selhub, J. (1992) Effect of vitamin B6 deficiency on fasting plasma homocysteine concentrations. Am. J. Clin. Nutr. 55: 11541160.
43. Bostom, A., Gohh, R., Beaulieu, A., Nadeau, M. R., Hume, A. L., Jacques, P. F., Selhub, J. & Rosenberg, I. H. (1997) Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann. Intern. Med. 127: 10891092.
44. Kim, Y.-I., Christman, J., Fleet, J., Cravo, M. L., Salomen, R. N., Smith, D., Ordovas, J., Selhub, J. & Mason, J. B. (1995) Moderate folate deficiency does not cause global hypomethylation of hepatic and colonic DNA or c-myc-specific hypomethylation of colonic DNA in rats. Am. J. Clin. Nutr. 61: 10831090.
45. Kim, Y.-I., Pogribny, I., Basnakian, A., Miller, A. G., Selhub, J., James, S. J. & Mason, J. B. (1997) Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am. J. Clin. Nutr. 65: 4652.
46. Henning, S., McKee, R. & Swendseid, M. (1989) Hepatic content of S-adenosylmethionine, S-adenosylhomocysteine, and glutathione in rats receiving treatments modulating methyl donor availability. J. Nutr. 119: 14781482.
47. Melnyk, S., Pogribna, M., Pogribny, I., Yi, P. & James, S. (2000) Measurement of plasma and intracellular S-adenosylmethionine and S-adenosylhomocysteine utilizing coulometric electrochemical detection. Clin. Chem. 46: 265272.
48. Yi, P., Melnyk, S., Pogribna, M., Pogribny, I. P., Hine, R. J. & James, S. J. (2000) Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA methylation. J. Biol. Chem. 275: 2931829323.
49. Robertson, K. & Jones, P. (2000) DNA methylation: past, present and future directions. Carcinogenesis 21: 461467.
50. Wainfan, E., Dizik, M., Stender, M. & Christman, J. K. (1989) Rapid appearance of hypomethylated DNA in livers of rats fed cancer-promoting, methyl-deficient diets. Cancer Res. 49: 40944097.
51. Balaghi, M. & Wagner, C. (1993) DNA methylation in folate deficiency: use of CpG methylase. Biochem. Biophys. Res. Commun. 193: 11841190.[Medline]
52. Pogribny, I., Basnakian, A., Miller, B., Lopatina, N. G., Poirier, L. A. & James, S. J. (1995) Breaks within genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res. 55: 18941901.
53. Rampersaud, G., Kauwell, G., Hutson, A., Cerda, J. J. & Bailey, L. B. (2000) Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am. J. Clin. Nutr. 72: 9981003.
54. Friso, S., Choi, S.-W., Dolnikowski, G. & Selhub, J.A method to assess genomic DNA methylation using high performance liquid chromatography/electrospray ionization mass spectromety. Anal. Chem., in press.
55. Blount, B., Mack, M., Wehr, C., MacGregor, J. T., Hiatt, R. A., Wang, G., Wickramasinghe, S. N., Everson, R. B. & Ames, B. N. (1997) Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage. Proc. Natl. Acad. Sci. USA 94: 32903295.
This article has been cited by other articles:
![]() |
J. Ishihara, H. Iso, M. Inoue, M. Iwasaki, K. Okada, Y. Kita, Y. Kokubo, A. Okayama, S. Tsugane, and for the JPHC Study Group Intake of Folate, Vitamin B6 and Vitamin B12 and the Risk of CHD: The Japan Public Health Center-Based Prospective Study Cohort I J. Am. Coll. Nutr., February 1, 2008; 27(1): 127 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Romieu, F. Castro-Giner, N. Kunzli, and J. Sunyer Air pollution, oxidative stress and dietary supplementation: a review Eur. Respir. J., January 1, 2008; 31(1): 179 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Morris, P. F Jacques, I. H Rosenberg, and J. Selhub Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification Am. J. Clinical Nutrition, January 1, 2007; 85(1): 193 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. N Husemoen, U. Toft, M. Fenger, T. Jorgensen, N. Johansen, and A. Linneberg The association between atopy and factors influencing folate metabolism: is low folate status causally related to the development of atopy? Int. J. Epidemiol., August 1, 2006; 35(4): 954 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chanson, T. Sayd, E. Rock, C. Chambon, V. Sante-Lhoutellier, G. Potier de Courcy, and P. Brachet Proteomic Analysis Reveals Changes in the Liver Protein Pattern of Rats Exposed to Dietary Folate Deficiency J. Nutr., November 1, 2005; 135(11): 2524 - 2529. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Girard and J. J. Matte Effects of Intramuscular Injections of Vitamin B12 on Lactation Performance of Dairy Cows Fed Dietary Supplements of Folic Acid and Rumen-Protected Methionine J Dairy Sci, February 1, 2005; 88(2): 671 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Franz A Functional Biological Marker is Needed for Diagnosing Magnesium Deficiency J. Am. Coll. Nutr., December 1, 2004; 23(6): 738S - 741S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Shaw, S. L. Carmichael, W. Yang, S. Selvin, and D. M. Schaffer Periconceptional Dietary Intake of Choline and Betaine and Neural Tube Defects in Offspring Am. J. Epidemiol., July 15, 2004; 160(2): 102 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Potischman and J. L. Freudenheim Biomarkers of Nutritional Exposure and Nutritional Status: An Overview J. Nutr., March 1, 2003; 133(3): 873S - 874. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||